Eledon Pharmaceuticals, Inc. (ELDN)
- Previous Close
2.0200 - Open
2.0500 - Bid 2.0000 x 100
- Ask 2.1200 x 100
- Day's Range
2.0004 - 2.0800 - 52 Week Range
1.0700 - 2.9500 - Volume
81,544 - Avg. Volume
88,619 - Market Cap (intraday)
51.115M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6400 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.60
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
eledon.comRecent News: ELDN
Performance Overview: ELDN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELDN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELDN
Valuation Measures
Market Cap
50.12M
Enterprise Value
-596.48k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.56%
Return on Equity (ttm)
-48.12%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-40.33M
Diluted EPS (ttm)
-1.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
51.1M
Total Debt/Equity (mrq)
0.46%
Levered Free Cash Flow (ttm)
-24.47M